AI Engines For more Details: Perplexity Kagi Labs You
Anticoagulant Effects: Argatroban inhibits the activity of thrombin, an enzyme involved in the clotting process. By inhibiting thrombin, argatroban helps to prevent the formation of blood clots and can also help dissolve existing clots.
Treatment of Heparin-Induced Thrombocytopenia (HIT): Argatroban is particularly useful in the management of heparin-induced thrombocytopenia (HIT), a potentially life-threatening condition characterized by a decrease in platelet count and increased risk of blood clot formation in patients receiving heparin therapy.
Perioperative Anticoagulation: Argatroban may be used as an alternative anticoagulant for patients who require perioperative anticoagulation and have a history of or are at risk for HIT.
Parenteral Administration: Argatroban is administered intravenously (IV), usually as a continuous infusion. This route of administration allows for precise control of anticoagulation and rapid onset of action.
Monitoring: Close monitoring of coagulation parameters such as activated partial thromboplastin time (aPTT) or activated clotting time (ACT) is necessary during argatroban therapy to ensure therapeutic anticoagulation while minimizing the risk of bleeding complications.
Individualized Dosing: The dose of argatroban may need to be adjusted based on individual patient factors such as renal function, hepatic function, and concomitant use of other medications that affect coagulation.
Bleeding Risk: Like other anticoagulants, argatroban increases the risk of bleeding, including minor bleeding (e.g., bruising, nosebleeds) and more serious bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage). Patients should be monitored closely for signs of bleeding during argatroban therapy.
Contraindications: Argatroban is contraindicated in patients with active bleeding, a history of hypersensitivity to argatroban, and those with severe liver disease. It should be used with caution in patients with renal impairment and in those at increased risk of bleeding due to other factors.
Drug Interactions: Argatroban may interact with other medications, particularly those that affect blood clotting or liver metabolism. Concurrent use of argatroban with other anticoagulants, antiplatelet agents, or medications that affect hepatic function should be carefully monitored.
Reversal Agent: Unlike some other anticoagulants such as heparin or warfarin, there is no specific antidote for argatroban. Management of bleeding complications during argatroban therapy may involve supportive measures and discontinuation or adjustment of the anticoagulant therapy.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 0.1 | 0.3 | -2 |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
| Allergies | 0.1 | -0.1 | |
| Allergy to milk products | 0.1 | 0.1 | |
| Alzheimer's disease | 0.3 | 0.7 | -1.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0 | 0 |
| Ankylosing spondylitis | 0.1 | -0.1 | |
| Anorexia Nervosa | 0.1 | -0.1 | |
| Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
| Asthma | 0 | 0 | |
| Atherosclerosis | 0.1 | 0 | 0 |
| Atrial fibrillation | 0.3 | 0.2 | 0.5 |
| Autism | 0.4 | 0.5 | -0.25 |
| Barrett esophagus cancer | 0 | 0 | |
| Bipolar Disorder | 0.2 | 0.3 | -0.5 |
| Carcinoma | 0.2 | 0 | 0 |
| Celiac Disease | 0.3 | -0.3 | |
| Cerebral Palsy | 0 | 0 | 0 |
| Chronic Fatigue Syndrome | 0.3 | 0.8 | -1.67 |
| Chronic Kidney Disease | 0.1 | 0.3 | -2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0.3 | 0 |
| Chronic Urticaria (Hives) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0 | 0 | |
| Colorectal Cancer | 0.1 | 0.1 | |
| Constipation | 0 | 0 | |
| Coronary artery disease | 0.1 | 0.3 | -2 |
| COVID-19 | 0.1 | 0.4 | -3 |
| Crohn's Disease | 0.6 | 0.3 | 1 |
| deep vein thrombosis | 0 | 0 | |
| Depression | 0.4 | 0.8 | -1 |
| Eczema | 0.1 | 0 | 0 |
| Endometriosis | 0.3 | 0 | 0 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0 | 0 | |
| Fibromyalgia | 0 | 0.5 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.3 | -2 |
| gallstone disease (gsd) | 0.1 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | |
| Generalized anxiety disorder | 0.1 | 0.3 | -2 |
| giant cell arteritis | 0 | 0 | |
| Gout | 0.3 | -0.3 | |
| Halitosis | 0 | 0 | |
| Hashimoto's thyroiditis | 0.2 | -0.2 | |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0 | 0 | 0 |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0 | 0.5 | 0 |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 0.1 | 0.4 | -3 |
| Insomnia | 0 | 0 | |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0 | 0 | |
| Irritable Bowel Syndrome | 0.1 | 0 | 0 |
| Liver Cirrhosis | 0.5 | 0.5 | 0 |
| Long COVID | 0.6 | 0.6 | 0 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0 | 0 | |
| ME/CFS with IBS | 0 | 0.5 | 0 |
| ME/CFS without IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 0.6 | 0.5 | 0.2 |
| Mood Disorders | 0.9 | 0.8 | 0.13 |
| Multiple Sclerosis | 0.3 | 0.1 | 2 |
| Multiple system atrophy (MSA) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0 | 0.3 | 0 |
| Obesity | 0.6 | 0.3 | 1 |
| obsessive-compulsive disorder | 0.1 | 0.3 | -2 |
| Osteoarthritis | 0.1 | 0 | 0 |
| Osteoporosis | 0.1 | 0.1 | |
| Parkinson's Disease | 0.5 | 0.3 | 0.67 |
| Polycystic ovary syndrome | 0.1 | 0.1 | 0 |
| Postural orthostatic tachycardia syndrome | 0 | 0.3 | 0 |
| Psoriasis | 0.1 | 0.3 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.3 | 1 |
| Rosacea | 0 | 0 | 0 |
| Schizophrenia | 0.5 | 0.3 | 0.67 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0 | 0 | |
| Stress / posttraumatic stress disorder | 0 | 0.3 | 0 |
| Systemic Lupus Erythematosus | 0.6 | 0 | 0 |
| Tic Disorder | 0 | 0 | |
| Type 1 Diabetes | 0.5 | 0 | 0 |
| Type 2 Diabetes | 0.6 | 0.3 | 1 |
| Ulcerative colitis | 0 | 0.5 | 0 |
| Unhealthy Ageing | 0.6 | 0.3 | 1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.